Capromab pendetide scanning has a potential role in optimizing patient selection for salvage cryosurgical ablation of the prostate

Urology

Volumn 76, Issue 5, 2010, Pages 1162-1167

  El Zawahry, Ahmed M ^a   Clarke, Harry S ^a   Eskridge, Matthew R ^a   Rieter, William ^a   Onicescu, Georgiana ^b   Garrett Mayer, Elizabeth ^b   Gordon, Leonie L ^a   Keane, Thomas E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; CAPROMAB PENDETIDE IN 111;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER STAGING; CRYOSURGERY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RISK FACTOR; SALVAGE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; CRYOSURGERY; DISEASE-FREE SURVIVAL; HUMANS; INDIUM RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78149361355     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.01.082     Document Type: Article

References (30)

1. P. Agarwal, N. Sadetsky, and B. Konety Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes Cancer 112 2008 307 314
2. G. Zagars, A. Pollack, and A. von Eschenbach Prostate cancer and radiation therapy: the message conveyed by serum prostate-specific antigen Int J Radiat Oncol Biol Phys 33 1995 23 35
3. S. Mehta, D. Lubeck, and N. Sadetsky Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE J Urol 171 2004 215 219
4. D. Loblaw, K. Virgo, and R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605
5. S. Basaria Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth J Androl 29 2008 534 539
6. N. Keating, A. O'Malley, and M. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
7. H. Tsai, A. D'Amico, and N. Sadetsky Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality J Natl Cancer Inst 99 2007 1516 1524
8. J. Ward, T. Sebo, and M. Blute Salvage surgery for radiorecurrent prostate cancer: contemporary outcomes J Urol 173 2005 1156
9. J. Izawa, L. Madsen, and S. Scott Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome J Clin Oncol 20 2002 2664
10. C. Ng, M. Moussa, and D. Downey Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome J Urol 178 2007 1253 1257
11. M. Allaf, G. Palapattu, and B. Trock Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer J Urol 172 2004 1840 1844
12. A. Lee, L. Levy, and R. Cheung Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy Int J Radiat Oncol Biol Phys 63 2005 456 462
13. P. Zhou, M. Chen, and D. McLeod Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Clin Oncol 23 2005 6992
14. M. Harisinghani, J. Barentsz, and P.F. Hahn Noninvasive detection of clinically occult lymph-node metastases in prostate cancer N Engl J Med 348 2003 2491 2499
15. M. Manyak, M. Javitt, and P. Kang The evolution of imaging in advanced prostate cancer Urol Clin North Am 33 2006 133
16. J. Rorvik, O. Halvorsen, and G. lbrektsen Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer Scand J Urol Nephrol 32 1998 116
17. M. Manyak, G. Hinkle, and J. Olsen Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer Urology 54 1999 1058
18. Weinerman P, Arger P, Coleman B, et al. Pelvic adenopathy from bladder and prostate carcinoma: detection by rapid-sequence computed tomography. AJR. 1983. Am J of Roentgenol.;140:95-99.
19. N. Borley, K. Fabrin, and S. Sriprasad Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in "high-risk" prostate cancer compared to MRI or CT Scand J Urol Nephrol 37 2003 382 386
20. S. Park, J. Goo, and C. Jo Receiver operating characteristic (ROC) curve: practical review for radiologists Korean J Radiol 5 2004 11 18
21. J. Lam, and A. Belldegrun Salvage cryosurgery of the prostate after radiation failure Rev Urol 6 2004 S27 S36
22. P. Nguyen, A. D'Amico, and A. Lee Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature Cancer 110 2007 1417 1428
23. K. Han, J. Cohen, and R. Miller Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience J Urol 170 2003 1126 1130
24. D. Sodee, A. Nelson, and P. Faulhaber Update on fused capromab pendetide imaging of prostate cancer Clin Prostate Cancer 3 2005 230 238
25. T. Wong, T. Turkington, and T. Polascik ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology AJR Am J Roentgenol 184 2005 676 680
26. R. Ellis, E. Kim, and R. Conant Radioimmunoguided imaging of prostate cancer foci with histopathological correlation Int J Radiat Oncol Biol Phys 49 2001 1281 1286
27. R. Ellis, H. Zhou, and E. Kim Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide Brachytherapy 6 2007 16 25
28. M. Haseman, S. Rosenthal, and S. Kipper Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer Urology 70 2007 303
29. D. Kahn, R. Williams, and M. Haseman Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy J Clin Oncol 16 1998 284 289
30. C. Thomas, P. Bradshaw, and B. Pollock Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy J Clin Oncol 21 2003 1715 1721